Alexza Completes Enrollment In Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) In Panic Disorder Patients
May 15th 2008Drug InformationAnxiety
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has completed the enrollment in its Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R) alprazolam) in patients with panic disorder. AZ-002 is an inhalation product candidate being developed for the acute treatment of panic attacks associated with panic disorder. AZ-002 is being developed through Symphony Allegro, a development collaboration formed between Alexza and Symphony Capital in 2006.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
